Beike Biotech of Shenzhen Unveils Cancer Immunotherapy Program
April 28, 2016 at 07:16 AM EDT
Beike Biotechnology, a Shenzhen company usually known for its stem cell products, declared that it has built a "strategic position" in cancer immunotherapy. In 2014, Beike acquired China rights to an immunotherapy from Altor Biosciences of Florida. One year later, the company acquired Nanjing Abingen Biotech, also an immunotherapy company. By adding its own R&D to its acquired technologies, Beike believes it can build a portfolio of cancer immunotherapies for China in the next few years. More details.... Share this with colleagues: // //